|
|
|
|
|
|
|
|
|
|
|
|
|
27.07.26 - 14:39
|
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer (Business Wire)
|
|
|
– Severino joins Sarepta's Board of Directors
– Doug Ingram to retire from SareptaCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.
Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to Tessera, he served as Vice Chairman and President at AbbVie, where he was responsible for research and development and the corporate strategy office. During his tenure at AbbVie, he oversaw a rapid expansion of AbbVie's pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precisio...
|
|
|
|
|
22.07.26 - 14:36
|
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futur...
|
|
|
10.07.26 - 18:06
|
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout (24/7 Wall St.)
|
|
|
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run. Moderna (NASDAQ:MRNA) stock is down 11% to $68.50, ImmunityBio (NASDAQ:IBRX) shares are off 8% to $8.16, and Sarepta Therapeutics (NASDAQ:SRPT) stock has slid 8% to $18.84. The moves are steep, but they land ... Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
